LigaChem Biosciences Bolsters Leadership with Appointment of Rodrigo Ruiz Soto as Chief Medical Officer

LigaChem Biosciences, a leading innovator in the development of antibody-drug conjugates (ADCs) for cancer treatment, has strengthened its executive team with the appointment of Dr. Rodrigo Ruiz Soto as Chief Medical Officer (CMO). This strategic move underscores the company's commitment to advancing its robust pipeline of therapeutic candidates and solidifying its position in the competitive oncology landscape.

Dr. Ruiz Soto brings over two decades of global experience in oncology clinical development to his new role. With a proven track record of success in senior leadership positions at renowned biopharmaceutical companies, he is well-equipped to drive LigaChem's clinical strategy and accelerate the development of its promising pipeline.

Prior to joining LigaChem, Dr. Ruiz Soto served as Senior Vice President of Clinical Development at Deciphera Pharmaceuticals, where he successfully led the clinical development function and oversaw the global approval of Ripretinib. His expertise spans a wide range of oncology indications, including solid tumors and hematological malignancies.

Dr. Ruiz Soto's appointment aligns perfectly with LigaChem's long-term strategic goals and market positioning. His extensive experience in oncology clinical development will be invaluable in advancing the company's ADC therapies and expanding its reach in the global market. His leadership will also be crucial in navigating the regulatory approval process, given his past success in securing FDA approvals.

In his new role, Dr. Ruiz Soto will be based at AntibodyChem Biosciences, the company's US subsidiary in Massachusetts. He will play a pivotal role in driving LigaChem's clinical programs and working towards bringing innovative therapies to market.

The appointment of Dr. Ruiz Soto as CMO is a testament to LigaChem's commitment to investing in top talent and driving innovation in the oncology space. As the company continues to grow and expand its pipeline, investors can expect to see significant progress in the development and commercialization of its ADC therapies. With Dr. Ruiz Soto at the helm of its clinical strategy, LigaChem is well-positioned to capitalize on the growing demand for targeted cancer treatments and deliver value to its shareholders.